News

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

“We are pleased to announce this new patent that is especially important for patient care as it enables ultra-fast, 30-second auto-calibration of arterial blood pressure, which is an essential measurement for cardiovascular health. This provides a big advantage over existing continuous blood pressure monitoring systems that require additional arm cuff calibration measurements, which add costly delays to set up time and patient care,” commented Jeff Pompeo, President and Chief Executive Officer of Caretaker Medical.

Caretaker Medical, a pioneer in wireless “beat-by-beat” hemodynamic monitoring technology, now has six issued patents in the U.S., Europe, and Asia, adding to the long-term value of our medical-grade VitalStream™ continuous patient monitoring system.

Learn more about Caretaker Medical here.

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …